143 related articles for article (PubMed ID: 23260091)
1. Optimization of methodology for production of CD25/CD71 allodepleted donor T cells for clinical use.
Albon SJ; Mancao C; Gilmour K; White G; Ricciardelli I; Brewin J; Lugthart G; Wallace R; Amrolia PJ
Cytotherapy; 2013 Jan; 15(1):109-21. PubMed ID: 23260091
[TBL] [Abstract][Full Text] [Related]
2. Functional characterization of alloreactive T cells identifies CD25 and CD71 as optimal targets for a clinically applicable allodepletion strategy.
Samarasinghe S; Mancao C; Pule M; Nawroly N; Karlsson H; Brewin J; Openshaw P; Gaspar HB; Veys P; Amrolia PJ
Blood; 2010 Jan; 115(2):396-407. PubMed ID: 19890093
[TBL] [Abstract][Full Text] [Related]
3. Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation.
Solomon SR; Tran T; Carter CS; Donnelly S; Hensel N; Schindler J; Bahceci E; Ghetie V; Michálek J; Mavroudis D; Read EJ; Vitetta ES; Barrett AJ
Cytotherapy; 2002; 4(5):395-406. PubMed ID: 12473206
[TBL] [Abstract][Full Text] [Related]
4. Selective depletion of alloreactive donor T cells leads to elimination of graft-versus-host reactivity and stimulates graft-versus-leukaemia/myeloma effect.
Matějková E; Foltánková V; Burešová I
Folia Biol (Praha); 2013; 59(4):146-53. PubMed ID: 24093772
[TBL] [Abstract][Full Text] [Related]
5. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses.
Amrolia PJ; Muccioli-Casadei G; Yvon E; Huls H; Sili U; Wieder ED; Bollard C; Michalek J; Ghetie V; Heslop HE; Molldrem JJ; Rooney CM; Schlinder J; Vitetta E; Brenner MK
Blood; 2003 Sep; 102(6):2292-9. PubMed ID: 12763937
[TBL] [Abstract][Full Text] [Related]
6. Antiviral immunity and T-regulatory cell function are retained after selective alloreactive T-cell depletion in both the HLA-identical and HLA-mismatched settings.
Davies JK; Koh MB; Lowdell MW
Biol Blood Marrow Transplant; 2004 Apr; 10(4):259-68. PubMed ID: 15077224
[TBL] [Abstract][Full Text] [Related]
7. Generation of Non-Alloreactive Antiviral Central Memory CD8 Human Veto T Cells for Cell Therapy.
Bachar-Lustig E; Lask A; Eidelstein Y; Or-Geva N; Gidron-Budovsky R; Nathansohn-Levy B; Eyrich M; Liu WH; Dang G; Miranda KC; Ramirez A; Kaur I; Rezvani K; Shpall E; Champlin RE; Nagler A; Shimoni A; Barnees-Kagan S; Reisner Y
Transplant Cell Ther; 2024 Jan; 30(1):71.e1-71.e13. PubMed ID: 37890590
[TBL] [Abstract][Full Text] [Related]
8. Generation of alloreactivity-reduced donor lymphocyte products retaining memory function by fully automatic depletion of CD45RA-positive cells.
Müller N; Landwehr K; Langeveld K; Stenzel J; Pouwels W; van der Hoorn MAWG; Seifried E; Bonig H
Cytotherapy; 2018 Apr; 20(4):532-542. PubMed ID: 29500069
[TBL] [Abstract][Full Text] [Related]
9. [Selective depletion of donor alloreactive T cells by using immuno-magnetic cell sorting].
Lü H; Chai YH; Xu J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):637-40. PubMed ID: 16129050
[TBL] [Abstract][Full Text] [Related]
10. Depletion of alloreactive donor T cells using immunomagnetic cell selection.
Fehse B; Goldmann M; Frerk O; Bulduk M; Zander AR
Bone Marrow Transplant; 2000 May; 25 Suppl 2():S39-42. PubMed ID: 10933186
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy with CD25/CD71-allodepleted T cells to improve T-cell reconstitution after matched unrelated donor hematopoietic stem cell transplant: a randomized trial.
Peggs KS; Albon SJ; Oporto Espuelas M; Irving C; Richardson R; Casanovas-Company J; Wallace R; Guvenel A; Ghorashian S; Collura A; Subramaniyam M; Flutter B; Popova B; Castro F; Lopes A; Champion K; Schofield O; Clifton-Hadley L; Taylor T; Farrell M; Adams S; Gilmour KC; Mackinnon S; Tholouli E; Amrolia PJ
Cytotherapy; 2023 Jan; 25(1):82-93. PubMed ID: 36220712
[TBL] [Abstract][Full Text] [Related]
12. Depletion of alloreactive T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T lymphocytes.
Hartwig UF; Nonn M; Khan S; Meyer RG; Huber C; Herr W
Bone Marrow Transplant; 2006 Feb; 37(3):297-305. PubMed ID: 16327814
[TBL] [Abstract][Full Text] [Related]
13. Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations.
Garderet L; Snell V; Przepiorka D; Schenk T; Lu JG; Marini F; Gluckman E; Andreeff M; Champlin RE
Transplantation; 1999 Jan; 67(1):124-30. PubMed ID: 9921808
[TBL] [Abstract][Full Text] [Related]
14. Clinical-scale selective depletion of alloreactive T cells using an anti-CD25 immunotoxin.
Michálek J; Collins RH; Vitetta ES
Neoplasma; 2003; 50(4):296-9. PubMed ID: 12937844
[TBL] [Abstract][Full Text] [Related]
15. CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation.
Maury S; Lemoine FM; Hicheri Y; Rosenzwajg M; Badoual C; Cheraï M; Beaumont JL; Azar N; Dhedin N; Sirvent A; Buzyn A; Rubio MT; Vigouroux S; Montagne O; Bories D; Roudot-Thoraval F; Vernant JP; Cordonnier C; Klatzmann D; Cohen JL
Sci Transl Med; 2010 Jul; 2(41):41ra52. PubMed ID: 20650872
[TBL] [Abstract][Full Text] [Related]
16. Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis.
Koh MB; Prentice HG; Lowdell MW
Bone Marrow Transplant; 1999 May; 23(10):1071-9. PubMed ID: 10373075
[TBL] [Abstract][Full Text] [Related]
17. Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69).
Fehse B; Frerk O; Goldmann M; Bulduk M; Zander AR
Br J Haematol; 2000 Jun; 109(3):644-51. PubMed ID: 10886218
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous generation of multivirus-specific and regulatory T cells for adoptive immunotherapy.
Lugthart G; Albon SJ; Ricciardelli I; Kester MG; Meij P; Lankester AC; Amrolia PJ
J Immunother; 2012 Jan; 35(1):42-53. PubMed ID: 22130159
[TBL] [Abstract][Full Text] [Related]
19. Depletion of T-cell receptor alpha/beta and CD19 positive cells from apheresis products with the CliniMACS device.
Schumm M; Lang P; Bethge W; Faul C; Feuchtinger T; Pfeiffer M; Vogel W; Huppert V; Handgretinger R
Cytotherapy; 2013 Oct; 15(10):1253-8. PubMed ID: 23993299
[TBL] [Abstract][Full Text] [Related]
20. Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity.
Hartwig UF; Nonn M; Khan S; Link I; Huber C; Herr W
Biol Blood Marrow Transplant; 2008 Jan; 14(1):99-109. PubMed ID: 18158966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
